Skip to main content

Table 1 Patient characteristicsa

From: Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain

Variable Number %
Breast cancer type   
   Ductal 98 82
   Lobular 10 8
   Ductal/lobular 2 2
   Uncertain 4 3
   Other 5 4
Grade   
   1 6 5
   2 41 34
   3 56 47
   Unknown 17 14
ER   
   Positive 51 42
   Negative 69 57
PR   
   Positive 40 34
   Negative 78 65
   Not determined 1 1
HER2   
   Positive (IHC3+) 51 42
   Positive (IHC2+ and FISH+) 6 5
   Negative 62 52
   Not determined 1 1
Chemotherapy before brain metastases   
   Yes, adjuvant, neoadjuvant 47 39
   Yes, for metastatic disease 9 7
   Yes, a combination thereof 47 39
   No 8 7
   Unknown 9 7
Endocrine therapy before brain metastasesb   
   Yes, adjuvant, neoadjuvant 31 26
   Yes, for metastatic disease 5 4
   Yes, a combination thereof 13 11
   No 66 55
   Unknown 5 4
Trastuzumab before brain metastasesc   
   Yes 30 53
   No 25 43
   Unknown 2 3
Chemotherapy after brain surgery   
   Yes 57 47
   No 47 39
   Unknown 16 13
Endocrine therapy after brain surgeryb   
   Yes 21 17
   No 86 72
   Unknown 13 11
Anti-HER2 therapy after brain surgeryc   
   Trastuzumab 9 16
   Lapatinib 7 12
   Sequentially both 3 5
Type of first progression   
   Local 2 2
   Regional 9 7
   Distant 106 88
   Combined local regional and/or distant 1 1
   Unknown 1 2
Dominant site of metastatic diseased   
   Soft tissue 3 2
   Bone 5 4
   Visceral 110 92
   Unknown 2 2
Age at breast cancer diagnosis (mean (range) years) 49 (26-80)
Age at brain metastasis surgery (mean (range) years) 52 (29-83)
  1. aPercentages may not sum to 100 because of rounding to full numbers; btamoxifen, aromatase inhibitors, or tamoxifen and aromatase inhibitors; cin HER2-positive patients (IHC3+ or IHC2+ and FISH+); dcategory of worst prognosis irrespective of the extent, in order: soft tissue, bone, visceral; see Materials and methods. Number of patients, 120. ER, estrogen receptor; HER2, epidermal growth factor receptor; PR, progesterone receptor; WBRT, whole-brain radiotherapy.